The European Health Community has warned that time is running out to secure patients’ interests in Brexit negotiations.
With Phase 2 of the negotiations looming, health groups across Europe have drawn up a list of crucial unanswered questions that must be answered by the European Union and UK negotiators to ‘put patients first’ in the negotiations.
These questions were set out at a meeting of a Coalition of Brussels based health stakeholders on February 21, and have been released in advance of the European Council meeting on March 22, where the guidelines for the negotiation of Phase 2 will be agreed. These focus on how to prioritize patient safety and public health in the Article 50 negotiations on the future relationship between the UK and the EU. Each speaker posed three questions of importance which will need resolving for patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze